NIH funding cuts delayed a promising childhood brain cancer trial. Patients lost time they didn't have.
NIH funding cuts delayed a promising childhood brain cancer trial. Patients lost time they didn't have. CNBC
1636 материалов по теме, собраны автоматически из проверенных источников
NIH funding cuts delayed a promising childhood brain cancer trial. Patients lost time they didn't have. CNBC
Leica Biosystems brings Tempus pathology products to Aperio AI Store, accelerating AI-powered capabilities for oncology research News-Medical
Penn helped test a promising mRNA cancer vaccine. Here’s what the trial means for the field. Inquirer.com
Researchers at Texas Children's Duncan Neurological Research Institute (Duncan NRI), Baylor College of Medicine and collaborating institutions report in Nature Cancer that stroke promotes glioma growth. They also identified cellular and molecular mediators involved in the process, linking brain injury to malignant…
The CD47 Signal That Oncology Trial Designers Are Misreading The Clinical Trial Vanguard
American Cancer Society Cancer Health Research Centers (CHERCs) 2026 Oncodaily
BSC Co-Leads Development of National Cancer Data Node to Accelerate Oncology Research HPCwire
Advocates call on Congress to bolster cancer research and prevention Dakota News Now
Narjust Florez: The Questions We Ask in Cancer Research Shape the Care We are Able to Provide Oncodaily
Recognizing the Researchers and Collaborations Moving Cancer Research Forward on World Cancer Research Day - AFCR Oncodaily
Double Your Impact in Support of World Cancer Research Day thanks to a $10,000 Matching Gift - Conquer Cancer the ASCO Foundation Oncodaily
Advancing Cancer Research for a Healthier Kenya – National Cancer Institute of Kenya Oncodaily
Pancreatic Cancer Action Network Collaborative Catalyst Research Award 2027 Oncodaily
Variety of Yale Cancer Center Research Highlights to be Presented at Radiation and Oncology Conference | Newswise Newswise
Targeting KDM2B or downstream protein complexes it recruits may exploit a vulnerability in high-risk medulloblastoma subgroups that currently lack targeted therapies, according to a study led by St. Jude Children's Research Hospital and Hopp Children's Cancer Center Heidelberg (KiTZ). The researchers found that Group…